GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
Y

Yungjin Pharm Co 003520.KS · KRW

Health Care · KRX · 🇰🇷 South Korea

Compare

806

-2.42%

Close of 9 Nov 2026, in KRW

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Yungjin Pharm Co

Its shares trade on KRX under the ticker 003520.KS. It has been listed since 25 June 1973. In the fiscal year to 31 December 2025, it reported revenue of ₩254.26bn and a net loss of ₩227.7m. At that date it held total assets of ₩262.38bn and shareholders' equity of ₩91.46bn.

Yungjin Pharm.Co., Ltd. engages in the development, production, and distribution of pharmaceuticals. The company is headquartered in Seoul, Seoul. The firm mainly manufactures and sells pharmaceutical products including antibiotics, respiratory drugs, anti-infective drugs, antipyretics, analgesics, central nervous system (CNS) drugs, gastrointestinal (GI) drugs, cardiovascular (CV) drugs, antihistamines, antifungals, antidiabetics, vitamin nutrients, antibiotic raw materials, and others. The firm also engages in the leasing of real estates.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Pharmaceuticals
Listed since
25 Jun 1973
Employees
610

Leadership

Pay as last reported

  • Mr. Gi Su LeePresident, Chief Executive Officer, Director, since 2022
  • Mr. Gyeong Bo KangManaging Director
  • Mr. Wung Yeol YangManaging Director
  • Mr. Jung Yeon ChoAssistant Managing Director
  • Mr. Jun ChoiAssistant Managing Director
  • Ms. Sin Yeong ChoiAssistant Managing Director
  • Mr. Hong Jun ParkAssistant Managing Director
  • Mr. Yeong Yeop GohNon-Executive Independent Director
  • Mr. Bung Nyeon KimNon-Executive Independent Director
  • Mr. Won Seop KimNon-Executive Independent Director
  • Geun Hyeok YooIR Contact Officer, since 2023

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Headquartered in Seoul with 610 employees
  • Produces and distributes a wide range of pharmaceutical products
  • Engages in both manufacturing and leasing of real estate

Weaknesses

  • No specific weaknesses mentioned in the provided information
  • No financial data or performance metrics provided
  • No details on market share or competitive positioning

Opportunities

  • Expansion into new pharmaceutical markets
  • Growth in the healthcare sector in South Korea
  • Potential for increased real estate leasing revenue

Threats

  • Competition in the pharmaceutical industry
  • Regulatory changes affecting drug manufacturing
  • Economic downturns impacting healthcare spending

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.